Abstract
A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have